UpdatesPress Release
SPARC secured a Rare Pediatric Disease Priority Review Voucher (PRV) from the FDA for Sezaby® approval.
Sun Pharma Advanced Research Company LimitedSPARC · Filed with the exchange
This tradable PRV offers strategic flexibility, accelerating SPARC's pipeline development to bring new therapies to patients faster, addressing unmet medical needs.
No comments yet. Be the first.